$0.740
-0.018 (-2.49%)At close
BRNS Comparative Benchmarking
In the context of the broader market, BRNS competes directly with industry leaders such as BYSI and ABVC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, BRNS's gross margin of N/A stands against BYSI's N/A and ABVC's N/A. Such benchmarking helps identify whether Barinthus Biotherapeutics PLC is trading at a premium or discount relative to its financial performance.
Barinthus Biotherapeutics PLC Financial Performance
The company reported total revenue of $14.97 million in Q3 2024 but has faced significant net losses, including -$10.58 million in Q2 2026. The gross margin is currently at 100% for Q3 2024, but this is not sustainable as revenue has dropped to zero in subsequent quarters.
Financials
Related articles
- Equal-Weight vs Cap-Weighted S&P 500: RSP vs SPY After October's Rotation and Nvidia's CEO ShockEqual weight vs cap weighted S&P 500: how RSP and SPY differ, why October 2026's rotation was the widest since 2009, and how to blend both after Nvidia's shock.
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.